WSL
NEOS

Western Standard LLC’s Neos Therapeutics, Inc NEOS Stock Holding History

Western Standard LLC’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-25,935
Closed -$33K – 47
2019
Q2 		$33K Buy
+25,935
New +$47.7K 0.02% 39

Other funds holding NEOS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Western Standard LLC's NEOS Position: Q3 2019 in Review

Western Standard LLC sold out of Neos Therapeutics, Inc (NEOS) in Q3 2019, closing a stake of 25,935 shares — an estimated $33K sold.

Western Standard LLC first reported a position in NEOS in Q2 2019 and held it in 1 quarter. The position peaked at $33K in Q2 2019. 51 funds tracked by Wall St. Rank hold NEOS as of Q3 2019.

  • Western Standard LLC reported no remaining Neos Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Western Standard LLC sold 25,935 Neos Therapeutics, Inc shares in Q3 2019, an estimated $33K.
  • Western Standard LLC first reported a position in Neos Therapeutics, Inc in Q2 2019 and held it in 1 quarter.
  • Western Standard LLC's Neos Therapeutics, Inc position peaked at $33K in Q2 2019.
  • 51 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2019.

Based on Western Standard LLC's 13F filing for Q3 2019, filed 14 Nov 2019.